Siplizumab during liver transplant for people with autoimmune liver disease
Tests siplizumab's safety in adults with autoimmune liver disease receiving a liver transplant.
Key facts
- Who runs it
- Elizabeth C. Verna
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- A Study of SIPLIZUMAB in AILD and LT Patients
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 8 people, planned
- Started
- 11 Sept 2024
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional
- Treatments tested
- Siplizumab
- Record updated
- 24 November 2025
Who can take part
The trial is looking for adults with autoimmune hepatitis (AIH) and/or primary sclerosing cholangitis (PSC) who are on the waiting list for a liver transplant. They get siplizumab around the time of the transplant.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Clinical diagnosis of AIH and/or PSC, listed for liver transplantation. People with a MELD-Na liver score above 30 at the time of transplant cannot join.
- Earlier treatment
- No earlier transplant. No other study drugs in the last 30 days or 5 half lives. No live-attenuated vaccine within 2 months of transplant.
- Biomarker or test result
- Positive blood test for Epstein-Barr virus (EBV) within 12 months of screening.
- Main reasons for not taking part
- Other significant liver disease, such as viral hepatitis, alcohol-related liver disease or biopsy-proven non-alcoholic steatohepatitis
- Acute liver failure, listing for more than one organ, or known cancer, including cholangiocarcinoma and hepatocellular carcinoma
- HIV-1, hepatitis B or hepatitis C infection, or untreated latent TB
- Pregnant, breastfeeding or unwilling to use contraception
- Kidney failure with dialysis or eGFR < 30 at transplant, or low white cell (WBC less than 2,000/mm3) or lymphocyte (< 200/mm3) counts
Show the full registry criteria (23)Hide the full registry criteria
Who can take part
- Able to provide informed consent
- Age ≥ 18 years old
- Clinical diagnosis of AIH and/or PSC
- Listed for liver transplantation
- Epstein-Barr virus (EBV) seropositive within 12 months of screening
Who cannot take part
- Prior transplant
- Listed for multiorgan transplant
- Other investigational products in the last 30 days or 5 half lives
- Alcohol use exceeding 30g/day for men or 20g/day for women, and/or known phosphatidylethanol (PETH) level >80 in the 3 months prior to LT
- Receipt of any live-attenuated vaccine within 2 months of transplant; ADDITIONAL exclusion criteria to be reviewed at the time of transplant
- Presence or history of significant liver disease other than AIH or PSC, including viral hepatitis, alcohol-related liver disease and biopsy-proven non-alcoholic steatohepatitis
- Acute liver failure
- Known malignancy, including cholangiocarcinoma and hepatocellular carcinoma
- Sero-positive for HIV-1
- Hepatitis C Virus (HCV) antibody or RNA positive (within 6 months of screening)
- HBsAg, hepatitis B virus (HBV) DNA or HBcAb positive (within 6 months of screening)
- Untreated latent TB infection as detected by QuantiFERON Gold Plus Interferon Gamma Release Assay (IGRA) (or current standard interferon gamma release assay for TB)
- Model for end-stage liver disease (MELD)-Na score >30
- Donor features of Donation after Cardiac Death (DCD), HCV Ab or nucleic acid testing (NAT+), HBcAb or HBsAg+, or blood types A, B, and O incompatible organ
- Leukopenia (WBC less than 2,000/mm3
- Absolute lymphocyte count < 200/mm3
- Renal failure with dialysis or with estimated glomerular filtration rate (eGFR) < 30 at the time of LT
- Pregnant/lactating or unwilling to use contraception
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in United States.
- Columbia University Irving Medical Center / NewYork-Presbyterian HospitalNew York, United StatesContact: Theresa Lukose, PharmDTaking people
About the trial
What the trial wants to find out
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.
Read full original descriptionShow less
Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.
All subjects will be followed in the study for 12 months post-LT.
The group in the trial
- Open LabelTreatment being tested
subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.
Treatment: Siplizumab
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)
- Plain-language title
- Siplizumab during liver transplant for people with autoimmune liver diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06455280, who can take part
- Record updated
- 24 November 2025